Results Page

There are many treatment options for chronic lung conditions. However, many of them are medications that mask the symptoms of the condition. We provide potential patients with the facts they need to make an informed choice. We disclose information about our treatment outcomes and patient experiences to ensure the highest level of transparency for our patients. We hope the findings below will help you make the right treatment choice for yourself.

 

Over 96.2% Patient Satisfaction

This score is based on results from patient satisfaction surveys between March 1, 2019 and August 31, 2019. Patient satisfaction surveys are administered to patients during their treatment visit.

 

Of 722 patients treated in this time frame, 696 patients responded to a 5-item survey:

  • Satisfaction with delivery of treatment
  • Friendliness of staff
  • Cleanliness of clinic
  • Courtesy and attentiveness of provider
  • Clinician’s ability to answer questions adequately

From the 3,447 total responses, 3,413 responses were either Very Good or Excellent. Very Good or Excellent responses were totaled and divided by the number of responses to equal an average score of 99.01 out of 100.

91.6% Positive Patient Outcomes for COPD at 3 Months

From June 02, 2014 to October 18, 2018 a total of 2,813 COPD patients were treated. In all, 2,008 COPD patients responded to the Clinical COPD Questionnaire (CCQ), a self-report instrument, to evaluate the patient perspective at 3 months after treatment. 

The CCQ is made up of 10 questions and measures 3 main factors: 

  • Symptom domain change
  • Mental status domain change 
  • Functional status domain change

A total of 91.6% of patients responding had a positive outcome, noting clinically significant improvement or no change. Of the total, 75% showed minimal clinically important difference (MCID) of 0.4 or more, and 16.6% of patients showed no change. Chronic lung conditions are degenerative in nature and tend to get worse over time. Therefore, no change is a positive outcome.

86.6% Positive Patient Outcomes for COPD at 1 Year

  • From June 02, 2014 to October 18, 2018 a total of 2,813 COPD patients were treated. In all, 754 COPD patients responded to the Clinical COPD Questionnaire (CCQ), a self-report instrument consisting of 10 questions, to evaluate the patient perspective at 1 year after treatment. 

A total of 86.6% of patients responding had a positive outcome, noting clinically significant improvement or no change. Of the total, 64.1% showed minimal clinically important difference (MCID) of 0.4 or more, and 22.5% of patients showed no change. Chronic lung conditions are degenerative in nature and tend to get worse over time. Therefore, no change is a positive outcome.

The study below includes data for improvement in quality of life for COPD and ILD patients based on the MCID (minimum clinically important difference) among each of the 3 CCQ domains.

Melissa M. Rubio (2019) Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease. J Clin Res Med Volume 2(4): 1–8.

88% Positive Patient Outcomes for Interstitial Lung Disease and Pulmonary Fibrosis at 3 Months

From June 02, 2014 to October 18, 2018 a total of 567 interstitial lung disease and pulmonary fibrosis patients were treated. In all, 399 ILD/PF patients responded to the Clinical COPD Questionnaire (CCQ), a self-report instrument, to evaluate the patient perspective at 3 months after treatment. While the questionnaire has COPD in the title, the questions are all not COPD specific and could be used for many chronic lung conditions.

The CCQ is made up of 10 questions and measures 3 main factors: 

  • Symptom domain change
  • Mental status domain change 
  • Functional status domain change

A total of 88% of patients responding had a positive outcome, noting clinically significant improvement or no change. Of the total, 66.2% showed minimal clinically important difference (MCID) of 0.4 or more, and 21.8% of patients showed no change. Chronic lung conditions are degenerative in nature and tend to get worse over time. Therefore, no change is a positive outcome.

71.8% Positive Patient Outcomes for Interstitial Lung Disease and Pulmonary Fibrosis at 1 Year

  • From June 02, 2014 to October 18, 2018 a total of 567 interstitial lung disease and pulmonary fibrosis patients were treated. In all, 125 ILD/PF patients responded to the Clinical COPD Questionnaire (CCQ), a self-report instrument consisting of 10 questions, to evaluate the patient perspective at 1 year after treatment. While the questionnaire has COPD in the title, the questions are all not COPD specific and could be used for many chronic lung conditions.

A total of 71.8% of patients responding had a positive outcome, noting clinically significant improvement or no change. Of the total, 47.6% showed minimal clinically important difference (MCID) of 0.4 or more, and 24.2% of patients showed no change. Chronic lung conditions are degenerative in nature and tend to get worse over time. Therefore, no change is a positive outcome.

The study below includes data for improvement in quality of life for COPD and ILD patients based on the MCID (minimum clinically important difference) among each of the 3 CCQ domains.

Melissa M. Rubio (2019) Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease. J Clin Res Med Volume 2(4): 1–8.

84.5% Positive Patient Outcomes for All Diagnosis at 3 Months

From June 02, 2014 to October 18, 2018 a total of 3,471 patients were treated. In all, 1,928 of those patients responded to the Clinical COPD Questionnaire (CCQ), a self-report instrument, to evaluate the patient perspective at 3 months after treatment. While the questionnaire has COPD in the title, the questions are all not COPD specific and could be used for many chronic lung conditions.

The CCQ is made up of 10 questions and measures 3 main factors: 

  • Symptom domain change
  • Mental status domain change
  • Functional status domain change

A total of 84.5% of patients responding had a positive outcome, noting clinically significant improvement or no change. Of the total, 73.8% showed minimal clinically important difference (MCID) of 0.4 or more, and 10.7% of patients showed no change. Chronic lung conditions are degenerative in nature and tend to get worse over time. Therefore, no change is a positive outcome.

77.2% Positive Patient Outcomes for All Diagnosis at 1 Year

  • From June 02, 2014 to October 18, 2018 a total of 3,471patients were treated. In all, 898 of those patients responded to the Clinical COPD Questionnaire (CCQ), a self-report instrument consisting of 10 questions, to evaluate the patient perspective at 1 year after treatment. While the questionnaire has COPD in the title, the questions are all not COPD specific and could be used for many chronic lung conditions.

A total of 71.8% of patients responding had a positive outcome, noting clinically significant improvement or no change. Of the total, 61.7% showed minimal clinically important difference (MCID) of 0.4 or more, and 15.5% of patients showed no change. Chronic lung conditions are degenerative in nature and tend to get worse over time. Therefore, no change is a positive outcome.

The study below includes data for improvement in quality of life for COPD and ILD patients based on the MCID (minimum clinically important difference) among each of the 3 CCQ domains.

Melissa M. Rubio (2019) Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease. J Clin Res Med Volume 2(4): 1–8.

 

No Downtime

Because cellular therapy is minimally invasive, patients return to their normal activities within 15 minutes of their procedure.

 

Number of Patients 

Since its inception, Lung Institute has treated 5,900 patients. Those dates are from May 14, 2013 to August 26, 2019.

 

Number of Treatments

Lung Institute has provided more than 8,000 treatments from May 14, 2013 to August 26, 2019. About 26% of patients return to our clinics for additional treatments due to the degenerative nature of chronic lung conditions.

 

Patient Testimonials

The patients offering statements about their treatments with Lung Institute were not paid to do so. Their opinions are their own statements and do not reflect the opinions of Lung Institute.

 

FDA-Cleared Medical Device 

 

The device our clinicians use to draw blood and return platelet-rich plasma-platelet concentrate is cleared by the U.S. Food and Drug Administration. Visit https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K103340 for further information.

*For more information, go to www.LungInstitute.com/Results.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.